Background: Advanced gastric cancer (AGC) and systemic chemotherapy are some of the risk factors for venous thromboembolism (VTE). However, the cumulative incidence, risk factors and prognostic impact of VTE have not been evaluated in Japanese patients with AGC. Methods: This retrospective study included patients who received fluoropyrimidine-based firstline chemotherapy for AGC between September 2009 and July 2015 at our institution. VTE was diagnosed by computed tomography scan and was managed by anticoagulant therapy. The cumulative incidence of VTE was estimated by the Kaplan-Meier method. Multivariate analysis was performed to identify the risk factors and prognostic impact of VTE. Results: Of 283 patients, 37 (13.1%) developed VTE before or during chemotherapy. The cumulative incidence of VTE was 8.7% at 6 months and 13.6% at 1 year. The independent risk factors for VTE were body mass index (BMI) of ≥25 kg/m 2 (HR 3.38, 95% CI 1.72-6.65, P < 0.01) and presence
Introduction
Gastric cancer is the fifth most common cancer and the third leading cause of cancer-related mortality worldwide (1) . In Japan, the standard first-line chemotherapy for advanced gastric cancer (AGC) is combination of fluoropyrimidine plus platinum, such as S-1 or capecitabine combined with cisplatin or oxaliplatin. However, the prognosis of AGC patients remains poor, with a median overall survival (OS) of around 13-14 months according to previous Phase III studies (2) (3) (4) (5) .
Venous thromboembolism (VTE) is recognized as a common complication of malignant diseases (6) (7) . As previously reported, the odds ratio for VTE in malignancy was 4.3 compared with no malignancy (8) . Moreover, cancer patients with VTE have a twofold or greater increase in mortality compared with cancer patients without VTE (9) . In one study on cancer patients receiving chemotherapy, VTE was the fourth leading cause and accounted for 3.5% of deaths (10) . Therefore, reduction of mortality secondary to VTE is important in improving the prognosis of cancer patients.
The cancer-related risk factors for VTE include the primary site, stage and histology. Gastric and pancreatic cancer are diseases that have a very high risk association with VTE. The incidence of VTE has been reported to be higher in metastatic disease than in regional disease; its high incidence in adenocarcinoma might be triggered by selectin-mucin interactions (11) (12) (13) (14) . Although recommended for metastatic AGC, chemotherapy itself also increases the risk for VTE through multiple mechanisms (15) . Specific chemotherapeutic agents, particularly platinum-based regimens, are known to be associated with higher rates of VTE (16) . Within this class of agents that are commonly used for AGC treatment, VTE risk was higher for cisplatin than for oxaliplatin (17) .
Anticoagulants are strongly recommended for the treatment of acute VTE (18) . Although these agents are highly efficacious and have acceptable safety profile in most patients, patients with cancer have more than two-fold higher risk of anticoagulant-related bleeding compared with patients without cancer (19) (20) . Bleeding is one of common complications in AGC patients that negatively affects a patient's quality of life. In AGC patients, the safety and prognostic impact of anticoagulant therapy for VTE during chemotherapy remains unknown (17, (21) (22) .
The aim of this retrospective study was to identify cumulative incidence and risk factors of VTE, as well as the impact on OS in Japanese patients with AGC receiving chemotherapy.
Methods

Patients
We retrospectively reviewed the records of metastatic or recurrent gastric cancer patients who received first-line chemotherapy between September 2009 and July 2015 at Chiba Cancer Center, Chiba, Japan. All data were extracted from our database. The recruitment criteria were as follows: (1) histologically proven adenocarcinoma of the stomach or gastroesophageal junction (GEJ); (2) presence of distant metastases or unresectable lesions; (3) no concomitant malignant diseases; (4) started first-line chemotherapy for AGC at our hospital; (5) for recurrent cases, recurrence that occurred after 6 months or more from the last dose of adjuvant chemotherapy and (6) no intake of anticoagulant agents for any comorbidity. All patients provided written informed consent before starting chemotherapy. The institutional review board of Chiba Cancer Center approved this retrospective study.
Chemotherapy
First-line chemotherapy for AGC comprised fluoropyrimidine-based regimens, with similar dosages and treatment schedules as those used in previous clinical trials (2) (3) (4) . Chemotherapy was discontinued when there was disease progression, occurrence of unexpected serious adverse events, or patient refusal. No patient required the use of a central venous catheter for infusion of anticancer agents.
Identification and treatment for venous thromboembolism
VTE was defined as deep vein thrombosis (DVT) and/or pulmonary embolism (PE) and was radiologically diagnosed by contrastenhanced computed tomography (CT). Patients with thromboses in the abdominal vein were excluded from this study. Contrastenhanced CT of the chest, abdomen and pelvis at a slice thickness of 5 mm was performed every 6-8 weeks to evaluate response to chemotherapy. Patients with symptoms suspicious for VTE underwent chest to lower extremity contrast-enhanced CT at a slice thickness of 1 mm.
Patients who were diagnosed to have VTE received anticoagulant therapy with single or combined heparin, warfarin and edoxaban for at least 6 months. The patients with massive VTE were treated with heparin followed by warfarin, whereas the patients with non-massive VTE were treated with warfarin or edoxaban. Edoxaban was used after approval in Japan in 2014. Lowmolecular weight heparin was not used for VTE treatment because it is not approved in Japan. Anticoagulant therapy was started on an outpatient or inpatient basis without cessation of chemotherapy. The dosage of warfarin was adjusted to maintain an international normalized ratio of 1.5-2.5.
Statistical analysis
Patient demographics and the anatomic distribution and type of VTE were summarized by descriptive statistics or contingency tables. The cumulative incidence of VTE was estimated by the Kaplan-Meier method. Time to occurrence of VTE was calculated from the date of initiation of chemotherapy to that of CT-confirmed diagnosis of VTE. Patients who had no events during the observation period were censored on the last follow-up date. The cut-off date of the observation period was 31 December 2015. The risk factors for occurrence of VTE were assessed by the Cox proportional hazards model. Covariates with P values less than 0.10 in the univariate analysis were included in the multivariate analysis with stepdown procedure.
OS was calculated from the date of initiation of first-line chemotherapy to the date of death due to any cause. OS was compared between patients with VTE (VTE+ group) and those without VTE (VTE− group) using the log-rank test. The hazard ratio of VTE for OS was estimated using the Cox proportional hazards model after adjusting for the other prognostic factors that had a P value of less than 0.10 in the univariate analysis. All analyses were two-sided and those with P values < 0.05 were considered statistically significant. All statistical analyses were performed using StatView ver 5.0 software (SAS Institute, Cary, NS, USA).
Results
Patient population
Between September 2009 and July 2015, 287 AGC patients were started on first-line chemotherapy at our institution. Among them, 283 patients were recruited in this study. Four patients were excluded because of concomitant malignancy (n = 3) and no histologically proven adenocarcinoma (n = 1). As shown in Table 1 Incidence, treatment and outcome of venous thromboembolism VTE was observed in 37 (13.1%) patients before chemotherapy (n = 5) or during the first-line (n = 21), second-line (n = 8), and third-line (n = 3) chemotherapy. PE, DVT and PE plus DVT were present in 16, 11 and 10 patients, respectively (Table 2) . Among the 37 patients diagnosed as VTE, 13 (35%) were symptomatic, whereas 24 patients (65%) had no symptoms. The reported symptoms were edema or pain of the lower extremities in 11 patients, neck pain in 1 and dyspnea in 1. The overall cumulative incidence of VTE was 8.7% at 6 months and 13.6% at 1 year (Fig. 1) . The details of treatment and outcomes of VTE are shown in Table 3 . Of 37 patients with VTE, 35 (95%) received anticoagulant therapy with warfarin in 20, heparin plus warfarin in 10, edoxaban in 3, and heparin in 2. The remaining two patients did not receive anticoagulant therapy because the VTEs were diagnosed retrospectively after the chemotherapy course. No patients underwent insertion of vena cava filter. In the 26 patients who were evaluated by CT after anticoagulant therapy, VTE resolved in 23 patients (88%) after a median duration of 65 (12-86) days. Recurrence of VTE occurred in three patients after completion of anticoagulant therapy for 6 months (n = 2) and during anticoagulant therapy (n = 1). Grade 3 anemia requiring blood transfusion due to bleeding from the primary lesion developed in two patients during anticoagulant therapy with heparin and warfarin (n = 1) and edoxaban (n = 1); the anemia resolved after cessation of anticoagulant administration. Therefore, in patients with primary AGC, the rate of severe bleeding under anticoagulant therapy was 6.3% (2/32). Nine patients died before the first CT evaluation after initiation of anticoagulant therapy; eight of these patients died due to disease progression and the remaining one died from VTE-related respiratory failure, which developed 4 days after the occurrence of PE despite heparin treatment.
Risk factors for venous thromboembolism
Univariate analysis revealed two covariates that were associated with VTE occurrence: presence of peritoneal metastasis (HR 2.11, 95% CI 1.06-4.22, P = 0.03) and BMI ≥ 25 kg/m 2 (HR 3.52, 95%
CI, 1.79-6.92, P < 0.01) ( Table 5) . On multivariate analysis, these covariates were shown to be independent risk factors for occurrence of VTE: presence of peritoneal metastasis (HR 2.01, 95% CI, 1.00-4.00, P < 0.05) and BMI ≥ 25 kg/m 2 (HR 3.38, 95% CI,
1.72-6.65, P < 0.01) ( Table 5 ).
Venous thromboembolism and overall survival
In the OS analysis, there were 254 events (90%): 36 (97%) occurred in VTE+ group and 218 events (89%) occurred in VTE− group.
There was no statistically significant difference in median OS between the VTE + and VTE− groups (13.4 vs. 11.7 months, respectively; P = 0.58) (Fig. 2) . Univariate analysis identified the following adverse prognostic factors: PS ≥ 2, the stomach as the primary site, >2 metastatic sites and presence of peritoneal and bone metastases (Table 4 ). Multivariate analysis showed that the independent prognostic factors for OS were number of metastatic sites, peritoneal metastasis and bone metastasis, not VTE (HR = 0.89; 95% CI, 0.62-1.28; P = 0.53) ( Table 4) .
Discussion
This study demonstrated an incidence of VTE that was consistent with that previously reported (12, 17, 22) . BMI ≥ 25 kg/m 2 and peritoneal metastasis were independent risk factors for VTE and had no negative impact on OS. In clinical practice, anticoagulant therapy can be safe for AGC patients, even in those with primary tumor. This is the first study that included uniform subjects with only AGC receiving first-line chemotherapy in Japanese population. Lee et al. reported that the incidence of VTE was 13.3% among 361 patients with Stage IV (M1) gastric cancer in Korea (12) . In the West, a similar incidence (7.9-11.4%) of thromboembolic events (TEs) during chemotherapy for AGC patients was reported (17, 22) . Although Asians were generally reported to be at a lower risk for VTE than Westerns (23) (24) , the rate of VTE was the same in AGC patients. The incidence of VTE in our Japanese study was consistent with those reported from Korea and the West. BMI ≥ 25 kg/m 2 was one of the independent factors for VTE.
Our results can be explained by the previously reported association between obesity and VTE. Obesity is generally known as a risk factor for VTE (25) (26) , because of a status of low-grade inflammation and increased levels of procoagulant and hypofibrinolytic agents (27) (28) (29) . Furthermore, high abdominal pressure increases venous pressure in the lower extremities and can induce venous stasis (30) (31) . Likewise, Khorana et al. showed that in Western patients with various cancers receiving chemotherapy, BMI > 35 kg/m 2 was an independent risk factor for VTE (odds ratio 2.5; 95% CI, 1.3-4.7) (32). Although the BMI at baseline differed according to race, extrapolation of these data to Asian patients might be difficult. In the present study, a BMI cut-off of 25 kg/m 2 was adopted based on the Japan Society for the Study of Obesity classification of obesity. The results of our study suggested that a BMI of ≥ 25 kg/m 2 was a risk factor for VTE; this might provide a helpful perspective in Japanese populations. Our study indicated the association between peritoneal metastasis and VTE. The mechanism for this association was not clearly described, but we speculate that the presence of ascites might have elevated the abdominal pressure and induced venous stasis (30) . VTE might be related to the aggressiveness of cancer biology (9) and might lead to fatal circulatory and respiratory complications due to acute PE. Tetzlaff et al. reported poor prognosis in the subgroup of chemotherapy-naïve AGC patients who experienced TEs, which included VTE and arterial thrombosis, at baseline or during chemotherapy (22) . Starling et al. showed that TEs were associated with poor OS; however, after exclusion of cases with arterial thrombosis (21) . From these reports and our study, VTE might not have a negative impact on the prognosis of AGC patients. The reason why VTE did not deteriorate survival could be thought in two points as follows, First, AGC patients had poor prognosis around about 1 year, so the negative impact of VTE might disappear. Second, AGC patients frequently received contrast-enhanced CT scan in treatment course, so VTE might be easy to be detected and treated at an early phase. However, careful interpretation of results is required because these studies were retrospective, analyses were not pre-planned, and detailed information about anticoagulant therapy was lacking. In this study, anticoagulant therapy during chemotherapy for AGC was safe and efficacious. Only two patients developed gastrointestinal bleeding, which was manageable. These two patients did not receive a chemotherapy regimen that included ramucirumab. Our results indicated that anticoagulant therapy could be administered safely in AGC patients, even in those with a primary lesion.
There were some limitations in this study. First, there might have been unrecognized bias in patient selection and data collection because this was a small retrospective study. Second, we conducted this study in a single institution; another multicenter, large cohort study may be required to validate and generalize our results. Third, we diagnosed VTE by contrast-enhanced CT scan alone, without ultrasound of the extremity; therefore, the incidence of VTE might be underestimated. Lastly, the estimated prognostic impact of VTE might be lower than the true value because occurrence of VTE was a time-varying covariate but we did not consider this point in this study.
In conclusion, high BMI and the presence of peritoneal metastasis could be risk factors for VTE in Japanese AGC patients before or during chemotherapy. VTE might have no negative impact on OS in these patients.
